RESUMO
BACKGROUND: Safety is an important consideration in decisions on treatment for patients with moderate-to-severe psoriasis and the study of drug safety is the main purpose of the BIOBADADERM registry. The combination of a biologic agent and a conventional systemic drug [generally methotrexate (MTX)] is a common treatment in clinical practice. However, there is a paucity of evidence from real-world practice on the safety of such combination regimens in the treatment of psoriasis. OBJECTIVES: The primary objective of this study was to ascertain whether the use of regimens combining biologic drugs with MTX in the management of moderate-to-severe psoriasis increases the risk of adverse events (AEs) or serious AEs (SAEs). We compared monotherapy using tumour necrosis factor (TNF), interleukin (IL)-17 and IL-23 inhibitors with the use of the same drugs in combination with MTX. METHODS: Using data from the BIOBADADERM registry, we compared biologic monotherapies with therapies that were combined with MTX. We estimated adjusted incidence rate ratios (aIRR) using a random effects Poisson regression with 95% confidence intervals for all AEs, SAEs, infections and serious infections and other AEs by system organ class. RESULTS: We analysed data from 2829 patients and 5441 treatment cycles, a total of 12 853 patient-years. The combination of a biologic with MTX was not associated with statistically significant increases in overall risk of AEs or SAEs in any treatment group. No increase in the total number of infections or serious infections in patients receiving combined therapy was observed for any group. However, treatment with a TNF inhibitor combined with MTX was associated with an increase in the incidence of gastrointestinal AEs (aIRR 2.50, 95% CI 1.57-3.98; P < 0.002). CONCLUSIONS: The risk of AEs and SAEs was not significantly increased in patients with moderate-to-severe psoriasis receiving different classes of biologic drugs combined with MTX compared with those on biologic monotherapy.
Assuntos
Produtos Biológicos , Psoríase , Humanos , Metotrexato , Estudos de Coortes , Psoríase/patologia , Sistema de Registros , Terapia Biológica , Produtos Biológicos/efeitos adversosRESUMO
BACKGROUND: Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. OBJECTIVE: To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. METHODS: The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug, using methotrexate as reference, were determined by means of a prospective cohort. RESULTS: Our study included 2845 patients (8954 treatment cycles; 9642 patient-years). Ustekinumab and secukinumab had the lowest rate of adverse events for several of the system organ classes, with a statistically significant decreased rate ratio (IRR of <1), whereas cyclosporine and infliximab had the highest, with an increased rate ratio (IRR of ≥5). LIMITATIONS: Observational study, drug allocation not randomized, depletion of susceptibles, and prescribed doses not registered. CONCLUSION: Our data provide comparative safety information in the real-life setting that could help clinicians selecting between available products.
Assuntos
Psoríase/tratamento farmacológico , Adulto , Idoso , Terapia Biológica/efeitos adversos , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Sistema de Registros , Espanha , Fatores de TempoRESUMO
Fixed-dose combination topical therapy with corticosteroid and vitamin D analog provides effective treatment and possible long-term management of psoriasis. The anti-inflammatory and immunomodulatory effects of corticosteroids and vitamin D analogs in treating psoriasis are well investigated; their complementary effects lead to the disruption of the inflammatory feedback loop underlying psoriasis pathogenesis. Recent preclinical data showed that combination therapy is more effective than monotherapies of the active ingredients in preventing activation of resting pro-inflammatory cells, inducing immunomodulation, reducing inflammatory responses by regulating T cell production, and normalizing keratinocytes. The increased understanding of the mechanism of action of fixed-dose combination therapy from preclinical studies is supported by several clinical studies. As the efficacy of topical therapy is correlated with the skin penetration of the active ingredients, new drug delivery systems have been developed. The fixed-dose combination Cal/BD aerosol foam creates a modified supersaturated formulation when applied to the skin, which is maintained for at least 26 h in the laboratory setting. Clinical studies have demonstrated superior efficacy of fixed-dose combination calcipotriol (Cal) 50 µg/g and betamethasone dipropionate (BD) 0.5 mg/g aerosol foam compared with monotherapies of the active ingredients. Furthermore, Cal/BD aerosol foam has shown significantly improved efficacy compared with more traditional formulations, such as Cal/BD ointment and gel, in other studies. Calcipotriol also mitigates risks associated with betamethasone dipropionate and vice versa, resulting in the favorable safety profile observed with fixed-dose combination treatment. Recent data also suggest that fixed-dose combination treatment could provide long-term management of psoriasis, although further clinical investigations are needed. Overall, these data support the value of fixed-dose combination therapy of corticosteroid and vitamin D analog and highlight the added potential of innovative drug delivery for the treatment of psoriasis. FUNDING: LEO Pharma.
RESUMO
BACKGROUND: Identifying patients likely to have very good or bad results from systemic psoriasis therapy could improve efficiency of therapy. OBJECTIVE: To develop prognostic models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis. METHODS: Multivariable logistic regression of a prospective multicenter cohort of psoriatic patients in clinical practice (6449 person-years of follow-up). We used as possible predictors demographic characteristics, comorbidities, characteristics of the psoriasis (type, PASI, arthritis), history of past therapy at entry in the cohort, and history of response to previous cycles while in the cohort. We defined good response to a treatment cycle as either cycle end due to disease remission or a cycle longer than 2 years that does not end later due to inefficacy in the follow-up period. Bad response to a treatment cycle was defined as a cycle that is finished due to inefficacy, based on the physician judgment, after more than 3 months of treatment. RESULTS: Patients with fewer previous therapies, lower body mass index, older at start of therapy, and with previous history of good responses to therapy are more likely to have positive results of therapy. However, the predictive characteristics of models are poor. CONCLUSION: Predictive models of clinical response to systemic drugs in psoriasis with the studied variables do not seem to outperform drug selection by a dermatologist.
Assuntos
Terapia Biológica , Fármacos Dermatológicos/uso terapêutico , Imunossupressores/uso terapêutico , Psoríase/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Ustekinumab/uso terapêutico , Adulto , Idoso , Índice de Massa Corporal , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Biológicos , Prognóstico , Estudos ProspectivosRESUMO
INTRODUCTION: Biologic medications increase dramatically the burden of a chronic and high prevalent disease like psoriasis. The objective of the study was to quantify the use of dose reduction or dose escalation strategies, not reflected in the drug summary of product characteristics, in clinical practice. METHODS: An observational, cross-sectional study of a subset of patients from the Spanish Registry for Systemic Treatments in Psoriasis (BIOBADADERM) treated for over six consecutive months with the same biologic agent. RESULTS: The study included 637 patients. At the cut-off date, the initial dose had been reduced in 223 patients (35%; 95% CI: 31.3-38.9%) and escalated in 46 (7.2%; 95% CI: 5.3-9.5%). When compared with the patients treated with standard doses, the patients on reduced doses had a lower PASI score at the cut-off date (a mean 2.6 versus 1; -1.6 points) and exhibited greater improvement in PASI since the start of biologic therapy (mean reduction over baseline 75% versus 87%). By contrast, the patients receiving an escalated dose had higher PASI scores (2.6 versus 8.0) and showed less improvement in PASI (75% versus 46.8%). CONCLUSION: Off-label doses of biologic agents for psoriasis are frequent in clinical practice. This information is especially relevant for pharmacoeconomic models.
Assuntos
Terapia Biológica/métodos , Uso Off-Label , Psoríase/tratamento farmacológico , Adulto , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Psoriasis has been related to metabolic syndrome (MS). Adipocytokines produced by white adipose tissue may be involved in the pathogenesis of psoriasis and its association with MS. Our objectives were to characterize the profile of a number of different inflammatory and atherogenic markers, vitamins, adipokines and cytokines and their potential involvement in MS in patients with moderate-to-severe psoriasis without joint involvement compared to anthropometrically matched controls, and to evaluate correlation with severity of the skin disease and changes after narrow-band UVB (NB-UVB) phototherapy. We designed a prospective cross-sectional study. Baseline waist circumference, body fat composition, lipid, carbohydrate and calcium metabolism profile, inflammation markers, homocysteine and vitamins D, B6, B12 and folic acid, leptin, resistin, omentin, lipocalin-2, adipocyte fatty acid-binding protein, retinol-binding protein-4 (RBP-4), interleukin-6, soluble tumour necrosis factor receptor 1 (sTNFR1) and interleukin-17 of 50 psoriasis patients and 50 gender, age and body mass index-matched controls were recorded, then evaluated after NB-UVB in the patients. The patients had higher baseline serum concentrations of leptin, RBP-4, lipocalin-2 and sTNFR1. Baseline psoriasis area and severity index correlated with serum concentrations of RBP-4 and lipocalin-2 only. Principal components analysis disclosed a component including vitamins B12, B6, folic acid, calcidiol and HDL-cholesterol that was only present in healthy controls and opposed to a cluster of variables which promote MS. This component was absent in the patients. Our results point to lipocalin-2 and RBP-4 as relevant mediators of the trend towards MS in psoriatic patients.
Assuntos
Lipocalinas/sangue , Síndrome Metabólica/sangue , Proteínas Proto-Oncogênicas/sangue , Psoríase/sangue , Psoríase/patologia , Proteínas Plasmáticas de Ligação ao Retinol/análise , Índice de Gravidade de Doença , Proteínas de Fase Aguda , Adulto , Biomarcadores/sangue , Criança , Pré-Escolar , Estudos Transversais , Progressão da Doença , Feminino , Humanos , Lactente , Leptina/sangue , Lipocalina-2 , Masculino , Síndrome Metabólica/complicações , Pessoa de Meia-Idade , Estudos Prospectivos , Psoríase/complicações , Receptores Tipo I de Fatores de Necrose Tumoral/sangue , Terapia Ultravioleta , Vitamina B 12/metabolismo , Adulto JovemRESUMO
OBJECTIVE: To describe the use of systemic therapy for psoriasis (biologic and nonbiologic [classic] drugs) in patients not adequately represented in randomized controlled trials (RCTs) and the risk of serious adverse events (SAEs) in these patients. DESIGN: A registry inception cohort was used. SETTING: Thirteen dermatology departments in Spain participated. PATIENTS: A consecutive sample of patients treated with biologics and a systematic sample of patients treated with classic systemic therapy were evaluated. A total of 1042 patients (2179 person-years) were included. EXPOSURE: Inadequate representation in trials was defined as the presence of any of the following factors: elderly age (>70 years); type of psoriasis other than chronic plaque psoriasis; history of infection caused by hepatitis B, hepatitis C, or human immunodeficiency virus; history of cancer (excluding nonmelanoma skin cancer); and chronic renal or hepatic disease. MAIN OUTCOME MEASURES: Serious adverse events as defined by the International Conference on Harmonization were evaluated. RESULTS: In all, 29.8% of patients receiving systemic therapy for psoriasis would not have been eligible for RCTs. These individuals had an increased risk of SAEs (incidence rate ratio, 2.7; 95% CI, 1.5-4.7). Patients exposed to biologics had an adjusted increased risk of SAEs (incidence rate ratio, 2.3; 95% CI, 1.1-4.8) that was similar in patients eligible and ineligible for RCTs. CONCLUSIONS: Patients ineligible for RCTs are an important proportion (30%) of those receiving systemic therapy for psoriasis. These patients have a higher risk of SAEs and should be closely monitored. Patients exposed to biologics (whether these patients are eligible for RCTs or ineligible) are susceptible to the same increase in risk of SAEs, but biologics add to a higher baseline risk in patients who are ineligible for RCTs. The risk-benefit ratio in ineligible patients receiving biologics might be different from the ratio in eligible patients.
Assuntos
Anti-Inflamatórios/efeitos adversos , Produtos Biológicos/efeitos adversos , Seleção de Pacientes , Psoríase/classificação , Psoríase/tratamento farmacológico , Adulto , Fatores Etários , Idoso , Anticorpos Monoclonais/efeitos adversos , Feminino , Humanos , Imunossupressores/efeitos adversos , Ceratolíticos/efeitos adversos , Masculino , Pessoa de Meia-Idade , Terapia PUVA/efeitos adversos , Modelos de Riscos Proporcionais , Ensaios Clínicos Controlados Aleatórios como Assunto , Medição de Risco , EspanhaRESUMO
Introducción. La terapia UVB de banda estrecha, considerada un tratamiento de primera elección en la psoriasis, se ha propuesto además como una alternativa eficaz en otras dermatosis inflamatorias. Se presenta la experiencia clínica obtenida en un grupo de pacientes afectados de prurigo nodular tratados con terapia UVB de banda estrecha. Material y método. Se llevó a cabo una evaluación de la respuesta clínica y sintomática, sin grupo control, de una serie de 15 pacientes afectados de prurigo nodular que recibieron un total de 22 ciclos de terapia UVB de banda estrecha administrados en una cabina de cuerpo entero. Resultados. Después de un número medio de 32 sesiones y una dosis media acumulada de 26,2 J/cm2 se observó una mejoría clinicosintomática superior al 50 % en el 73 % de los ciclos terapéuticos completados (16/22), considerándose en remisión completa el 23 % (5/22). Discusión y conclusiones. Los datos aportados sugieren que la terapia UVB de banda estrecha puede ser una alternativa terapéutica bien tolerada y moderadamente eficaz en el prurigo nodular (AU)
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Prurigo/terapia , Terapia Ultravioleta/métodos , Fototerapia/métodos , Resultado do Tratamento , Satisfação do PacienteRESUMO
La UVB terapia de banda estrecha se considera en la actualidad una firme alternativa a la UVB terapia convencional y a la PUVA terapia en el tratamiento de la psoriasis moderada o extensa. Aportamos la experiencia en UVB terapia de banda estrecha obtenida a partir del estudio retrospectivo de pacientes con psoriasis que siguieron esta opción terapéutica en el Servicio de Dermatología de nuestro hospital en el período comprendido entre enero de 1995 y diciembre de 1999. A partir de los datos registrados se intentaron determinar factores clínicos predictivos del grado de respuesta o de la incidencia de efectos secundarios. En total se incluyeron en el estudio 54 pacientes (28 varones y 26 mujeres). La respuesta fue excelente en el 70% de los casos y moderada en el 8%, considerándose, en su conjunto, satisfactoria en el 78% de pacientes tratados. El antecedente de haber recibido tratamientos sistémicos, la afectación de más del 75% del territorio cutáneo y el desarrollo de efectos secundarios moderados durante el tratamiento se identificaron como factores predictivos de una peor respuesta. La incidencia de efectos secundarios moderados fue del 15%, siendo éstos más frecuentes en los pacientes varones, en aquellos de fototipo II y en la forma clínica de psoriasis en placas. La dosis acumulada media fue de 22 J/cm2 (intervalo: 2-73), con un número medio de sesiones de 31 (intervalo: 7-70). Por grupos, la dosis acumulada media fue menor en los pacientes de sexo femenino, en la variante en gotas y en pacientes de fototipo III. Teniendo en cuenta su elevada eficacia y la baja incidencia de efectos secundarios, la UVB terapia de banda estrecha puede considerarse dentro de la primera línea de tratamiento en la psoriasis moderada y extensa (AU)